Avalanche Biotechnologies, Inc. (AAVL) has 9 open-market insider trades by 9 insiders since 2014. The most active filer is Deerfield Special Situations Fund, L.P., 10%.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Deerfield Special Situations Fund, L.P. via James E. Flynn | 10% | — | 1 | $31.9M | 2014-08-05 |
| Pharmaceuticals Inc Regeneron | 10% | — | 1 | $10.0M | 2014-08-05 |
| Anders D. Hove | 10% | — | 1 | $6.8M | 2014-08-05 |
| VHCP Co-Investment Holdings II, LLC | 10% | — | 1 | $6.8M | 2014-08-05 |
| Mark S. Blumenkranz | Dir | — | 1 | $5.5M | 2016-02-12 |
| Llc Zygtech | 10% | — | 1 | $5.5M | 2015-04-14 |
| Steven Daniel Schwartz | Dir | — | 1 | $5.0M | 2016-02-12 |
| Thomas W. Chalberg | CEO | — | 1 | $4.7M | 2015-05-05 |
| Paul Wachter | Dir | — | 1 | $776K | 2016-02-29 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Mehdi Gasmi | VP & Pharmaceutical Development | Sell | $19K | 2015-05-28 |
| Steven Daniel Schwartz | Director | Sell | $648K | 2015-05-22 |
| Mehdi Gasmi | VP & Pharmaceutical Development | Sell | $19K | 2015-05-21 |
| Mark S. Blumenkranz | Director | Sell | $37K | 2015-05-19 |
| Steven Daniel Schwartz | Director | Sell | $570K | 2015-05-08 |
| Mehdi Gasmi | VP & Pharmaceutical Development | Sell | $17K |
Companies that share insiders with AAVL, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2015-05-07 |
| Thomas W. Chalberg | CEO | Sell | $750K | 2015-05-05 |
| Linda Bain | CFO | Sell | $79K | 2015-05-04 |
| Hans Hull | SVP & Business Operations | Sell | $154K | 2015-05-04 |
| Paul Wachter | Director | Sell | $37K | 2015-05-04 |
| Mark S. Blumenkranz | Director | Sell | $647K | 2015-05-01 |
| Mehdi Gasmi | VP & Pharmaceutical Development | Sell | $36K | 2015-04-28 |
| Paul Wachter | Director | Sell | $42K | 2015-04-27 |
| Steven Daniel Schwartz | Director | Sell | $652K | 2015-04-23 |
| Mehdi Gasmi | VP & Pharmaceutical Development | Sell | $39K | 2015-04-21 |